Using AI to find biomarkers that improve treatment for gastric cancer
Using artificial intelligence to discover spatial, genomic, and pathologic biomarkers to guide and augment immune checkpoint inhibitor therapy for gastric cancer
This study is looking to help people with gastric cancer by using artificial intelligence to find clues that show who might respond well to certain immune treatments, so they can get the best care possible.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11063978 on NIH RePORTER |
What this research studies
This research aims to enhance treatment outcomes for gastric cancer patients by utilizing artificial intelligence to identify biomarkers that predict responses to immune checkpoint inhibitors (ICIs). The study will analyze various data types, including genomic and pathologic information, to better understand the tumor microenvironment and refine ICI therapy. By collaborating closely with experts in computational science and surgery, the research seeks to develop strategies that not only identify which patients are likely to benefit from ICIs but also improve the effectiveness of these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gastric cancer who are considering or currently undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with gastric cancer who are not eligible for immune checkpoint inhibitor therapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for gastric cancer patients, potentially improving survival rates and reducing unnecessary side effects.
How similar studies have performed: Previous research has shown promise in using artificial intelligence to identify biomarkers in other cancers, suggesting that this approach may also be effective for gastric cancer.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Wang, Sam C. — Ut Southwestern Medical Center
- Study coordinator: Wang, Sam C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.